Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.42 |
| ▸ | CDK2 | P24941 | 4/20 | 0.42 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.42 |
| ▸ | ADK | P55263 | 5/20 | 0.42 |
| ▸ | HSPA8 | P11142 | 2/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1737251 | 0.80 | ABL1 (0.42) | DYRK1ACDK5CDK5R1CCNA2CDK2 | |
| SCHEMBL6738031 | 0.80 | ABL1 (0.42) | DYRK1ACDK5CDK5R1CCNA2CDK2 | |
| SCHEMBL6868829 | 0.72 | P2RX3 (0.38) | DYRK1ACDK5CDK5R1CCNA2CDK2 | |
| SCHEMBL6873394 | 0.72 | P2RX3 (0.39) | DYRK1ACDK5CDK5R1CCNA2CDK2 | |
| SCHEMBL6873391 | 0.72 | P2RX3 (0.39) | DYRK1ACDK5CDK5R1CCNA2CDK2 | |
| SCHEMBL6873374 | 0.71 | P2RX3 (0.38) | DYRK1ACDK5CDK5R1CCNA2CDK2 | |
| SCHEMBL6868826 | 0.70 | P2RX3 (0.39) | DYRK1ACDK5CDK5R1CCNA2CDK2 | |
| SCHEMBL30582621 | 0.69 | DYRK1A (1.00) | DYRK1ACDK5CDK5R1CCNA2CDK2 | |
| SCHEMBL15233798 | 0.66 | CDK1 (0.74) | CCNA2CDK2CCNA1ADKHSPA8 | |
| SCHEMBL13064460 | 0.66 | ADK (0.54) | ADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6831069-B2 | Having substituents at the C4' and C5' positions of the ribofuranose moiety; anticancer and immunomodulating effects at reduced cytotoxicity; treating autoimmune diseases, cancer, dermatitis | RIBAPHARM INC. | 2004-12-14 | — | — | US | disclosed |
| US-20020035077-A1 | Pyrrolo[2,3-d]pyrimidine nucleoside analogs | CEQUENT PHARMACEUTICALS, INC. | 2002-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035077-A1 | Pyrrolo[2,3-d]pyrimidine nucleoside analogs | TYMP, DPYD, TYMS | DYRK1A 3331/4885CDK5 478/4885CDK5R1 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.